Phase II Trial of Bortezomib and Vorinostat in Mantle Cell and Diffuse Large B-Cell Lymphomas
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 30 May 2017
At a glance
- Drugs Bortezomib (Primary) ; Vorinostat (Primary)
- Indications Diffuse large B cell lymphoma; Mantle-cell lymphoma
- Focus Therapeutic Use
- 30 Apr 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 04 Mar 2013 Planned End Date changed from 1 Apr 2012 to 1 Jun 2017 as reported by ClinicalTrials.gov.
- 31 Jul 2012 Additional lead trial investigators and associated centres added as reported by ClinicalTrials.gov.